Premium Insights - page 3 | BiopharmaTrend

New LLMs, Agents, and Graphs in Life Sciences

In recent weeks, Anthropic announced “Claude for Life Sciences” as an AI framework for assisting life science researchers. The release is one of several recent moves by general-purpose AI vendors …

Continue ›››

How AI Powers Synthetic Biology

Let's face it, we are living in a "century of biology" and artificial intelligence is a growing enabler of what comes next. For billions of years, evolution was the only …

Continue ›››

Inside Big Pharma's AI Playbook: From Molecule Discovery to Clinical Trials

7 fronts where Big Pharma explores AI via partnerships and internal programs. The traditional drug discovery process is among the most complex, costly, and time-consuming endeavors in science. Developing a …

Continue ›››

How Tech Giants like NVIDIA, Google, and Microsoft Are Targeting New Niches in Biopharma R&D

Tech giants are becoming part of biopharma’s infrastructure, applying AI, data, and cloud to drug discovery as they seek footholds in new markets. Large technology companies aren’t newcomers to biopharma …

Continue ›››

Biotech in Space: Microgravity, Ventures, and the Path to Production

From public labs to private stations, the near-term outlook for orbital bioprocessing and its first commercial pipelines The renewed surge in space ambition extends beyond rockets and habitats by driving …

Continue ›››

Digital Pathology: Slides, AI, & Challenges

Pathology has progressed from glass slides to AI-driven digital diagnostics, promising to transform disease detection while facing adoption and market challenges Bo Wang, Head of Biomedical AI at Xaira Therapeutics, puts it …

Continue ›››

Building the Virtual Cell: AI Foundation Models and Billion-Cell Datasets

From early 2000s and a 2012 milestone to a decade-long quiet—virtual cell modeling is resurging with transformers, perturbation atlases, and lab-in-the-loop systems While the term “virtual cell” initially goes back …

Continue ›››

H1 2025 Recap: Key Signals from the Tech+Bio Frontier

A high-signal summary of some of the most important moves and trends shaping biotech and tech-enabled life sciences in the first half of 2025. In this issue: Financial Climate & …

Continue ›››

How Organoids and AI Are Replacing Animal Testing

As FDA & NIH formalize support for non-animal testing, organ-on-a-chip, organoids, and ML-based toxicity models are being integrated into preclinical workflows by both startups and established pharma. On April 10th, …

Continue ›››

Can AI Diagnose Better Than Humans?

A week ago, Microsoft released the AI Diagnostic Orchestrator (MAI-DxO), a platform designed to utilize five large language model agents functioning as a panel of virtual doctors to develop disease …

Continue ›››

Emerging Brain-Computer Interface Industry Across Chips, AI, and Regulation

From surgically embedded chips, adaptive neuroheadsets, and AI-steered interfaces to the intensifying geopolitical contest In summer 2016 Noland Arbaugh, a student of Texas A&M University, suffered spinal cord injury during lake …

Continue ›››

12 Startups Applying AI to Gene Editing: From Custom CRISPR to Zinc-Finger Revivals

In May 2025, clinicians at Children’s Hospital of Philadelphia and Penn Medicine successfully performed a personalized CRISPR-based therapy on a newborn diagnosed with CPS1 deficiency—a rare genetic disorder impairing ammonia clearance in the liver. Built …

Continue ›››